Changes in sample size and length of follow-up to maintain power in the coronary artery bypass graft (CABG) Patch Trial

J. Thomas Bigger, Michael K. Parides, Linda M. Rolnitzky, Paul Meier, Bruce Levin, Debra A. Egan

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

The CABG Patch Trial is testing the hypothesis that prophylactic use of implantable cardiac defibrillators (ICDs) will improve survival in high-risk coronary heart disease patients undergoing CABG surgery. The original design called for 800 patients to be randomized to ICD prophylaxis or to no therapy and followed for 2 to 6.5 years (average, 40 months) to a common termination date. Since the ICD pulse generators used in this trial lasted about 42 months, the original design required ICD replacement in many patients. At its first two meetings in 1993, the Data and Safety Monitoring Board (DSMB) formalized a plan to adjust sample size in October 1994 if the control group mortality rate was lower than expected. In June 1994, an unanticipated and unique event - a subpoena from the Office of the Inspector General (OIG) - made it impossible to replace about half of the ICD generators and threatened to shorten follow-up substantially. If follow-up had been stopped on the date originally planned, but without replacing ICDs, the average follow-up would have fallen from 40 months to about 33 months. Also, in October 1994, the control group mortality rate was found to be somewhat lower than expected. Together, the abbreviated follow-up and lower control group mortality threatened to reduce power substantially. The DSMB reviewed several options for restoring power. Because mortality rates in the first month after CABG surgery were about seven times as high as thereafter and because ICD therapy did not reduce surgical mortality (death during the first 30 days), extending the follow-up benefits power more than does increasing the sample size. However, the limit on extending follow-up was 42 months (the expected battery life of the ICD). Data from the ICD-treated group was not reviewed or considered in making the decision. After reviewing many options for restoring power, the DSMB recommended that the sample size be increased from 800 to 900 patients and that almost all patients be followed for 42 months. This recommendation extended follow-up for 2 years beyond the original termination date planned for the trial and dictated that patients close out after 42 months rather than on a common termination date.

Original languageEnglish (US)
Pages (from-to)1-14
Number of pages14
JournalControlled Clinical Trials
Volume19
Issue number1
DOIs
StatePublished - Feb 1 1998
Externally publishedYes

Fingerprint

Implantable Defibrillators
Coronary Artery Bypass
Sample Size
Transplants
Clinical Trials Data Monitoring Committees
Mortality
Control Groups
Coronary Disease
Decision Making
Survival
Power (Psychology)
Therapeutics

Keywords

  • Arrhythmia
  • Clinical trial
  • Coronary artery bypass graft surgery
  • Group sequential monitoring
  • Implantable cardiac defibrillator
  • Sample size
  • Statistical power
  • Survival analysis

ASJC Scopus subject areas

  • Pharmacology

Cite this

Changes in sample size and length of follow-up to maintain power in the coronary artery bypass graft (CABG) Patch Trial. / Bigger, J. Thomas; Parides, Michael K.; Rolnitzky, Linda M.; Meier, Paul; Levin, Bruce; Egan, Debra A.

In: Controlled Clinical Trials, Vol. 19, No. 1, 01.02.1998, p. 1-14.

Research output: Contribution to journalReview article

Bigger, J. Thomas ; Parides, Michael K. ; Rolnitzky, Linda M. ; Meier, Paul ; Levin, Bruce ; Egan, Debra A. / Changes in sample size and length of follow-up to maintain power in the coronary artery bypass graft (CABG) Patch Trial. In: Controlled Clinical Trials. 1998 ; Vol. 19, No. 1. pp. 1-14.
@article{7452b3d3494a4c49b8d3fb5a053303fa,
title = "Changes in sample size and length of follow-up to maintain power in the coronary artery bypass graft (CABG) Patch Trial",
abstract = "The CABG Patch Trial is testing the hypothesis that prophylactic use of implantable cardiac defibrillators (ICDs) will improve survival in high-risk coronary heart disease patients undergoing CABG surgery. The original design called for 800 patients to be randomized to ICD prophylaxis or to no therapy and followed for 2 to 6.5 years (average, 40 months) to a common termination date. Since the ICD pulse generators used in this trial lasted about 42 months, the original design required ICD replacement in many patients. At its first two meetings in 1993, the Data and Safety Monitoring Board (DSMB) formalized a plan to adjust sample size in October 1994 if the control group mortality rate was lower than expected. In June 1994, an unanticipated and unique event - a subpoena from the Office of the Inspector General (OIG) - made it impossible to replace about half of the ICD generators and threatened to shorten follow-up substantially. If follow-up had been stopped on the date originally planned, but without replacing ICDs, the average follow-up would have fallen from 40 months to about 33 months. Also, in October 1994, the control group mortality rate was found to be somewhat lower than expected. Together, the abbreviated follow-up and lower control group mortality threatened to reduce power substantially. The DSMB reviewed several options for restoring power. Because mortality rates in the first month after CABG surgery were about seven times as high as thereafter and because ICD therapy did not reduce surgical mortality (death during the first 30 days), extending the follow-up benefits power more than does increasing the sample size. However, the limit on extending follow-up was 42 months (the expected battery life of the ICD). Data from the ICD-treated group was not reviewed or considered in making the decision. After reviewing many options for restoring power, the DSMB recommended that the sample size be increased from 800 to 900 patients and that almost all patients be followed for 42 months. This recommendation extended follow-up for 2 years beyond the original termination date planned for the trial and dictated that patients close out after 42 months rather than on a common termination date.",
keywords = "Arrhythmia, Clinical trial, Coronary artery bypass graft surgery, Group sequential monitoring, Implantable cardiac defibrillator, Sample size, Statistical power, Survival analysis",
author = "Bigger, {J. Thomas} and Parides, {Michael K.} and Rolnitzky, {Linda M.} and Paul Meier and Bruce Levin and Egan, {Debra A.}",
year = "1998",
month = "2",
day = "1",
doi = "10.1016/S0197-2456(97)00124-4",
language = "English (US)",
volume = "19",
pages = "1--14",
journal = "Controlled Clinical Trials",
issn = "0197-2456",
publisher = "Elsevier BV",
number = "1",

}

TY - JOUR

T1 - Changes in sample size and length of follow-up to maintain power in the coronary artery bypass graft (CABG) Patch Trial

AU - Bigger, J. Thomas

AU - Parides, Michael K.

AU - Rolnitzky, Linda M.

AU - Meier, Paul

AU - Levin, Bruce

AU - Egan, Debra A.

PY - 1998/2/1

Y1 - 1998/2/1

N2 - The CABG Patch Trial is testing the hypothesis that prophylactic use of implantable cardiac defibrillators (ICDs) will improve survival in high-risk coronary heart disease patients undergoing CABG surgery. The original design called for 800 patients to be randomized to ICD prophylaxis or to no therapy and followed for 2 to 6.5 years (average, 40 months) to a common termination date. Since the ICD pulse generators used in this trial lasted about 42 months, the original design required ICD replacement in many patients. At its first two meetings in 1993, the Data and Safety Monitoring Board (DSMB) formalized a plan to adjust sample size in October 1994 if the control group mortality rate was lower than expected. In June 1994, an unanticipated and unique event - a subpoena from the Office of the Inspector General (OIG) - made it impossible to replace about half of the ICD generators and threatened to shorten follow-up substantially. If follow-up had been stopped on the date originally planned, but without replacing ICDs, the average follow-up would have fallen from 40 months to about 33 months. Also, in October 1994, the control group mortality rate was found to be somewhat lower than expected. Together, the abbreviated follow-up and lower control group mortality threatened to reduce power substantially. The DSMB reviewed several options for restoring power. Because mortality rates in the first month after CABG surgery were about seven times as high as thereafter and because ICD therapy did not reduce surgical mortality (death during the first 30 days), extending the follow-up benefits power more than does increasing the sample size. However, the limit on extending follow-up was 42 months (the expected battery life of the ICD). Data from the ICD-treated group was not reviewed or considered in making the decision. After reviewing many options for restoring power, the DSMB recommended that the sample size be increased from 800 to 900 patients and that almost all patients be followed for 42 months. This recommendation extended follow-up for 2 years beyond the original termination date planned for the trial and dictated that patients close out after 42 months rather than on a common termination date.

AB - The CABG Patch Trial is testing the hypothesis that prophylactic use of implantable cardiac defibrillators (ICDs) will improve survival in high-risk coronary heart disease patients undergoing CABG surgery. The original design called for 800 patients to be randomized to ICD prophylaxis or to no therapy and followed for 2 to 6.5 years (average, 40 months) to a common termination date. Since the ICD pulse generators used in this trial lasted about 42 months, the original design required ICD replacement in many patients. At its first two meetings in 1993, the Data and Safety Monitoring Board (DSMB) formalized a plan to adjust sample size in October 1994 if the control group mortality rate was lower than expected. In June 1994, an unanticipated and unique event - a subpoena from the Office of the Inspector General (OIG) - made it impossible to replace about half of the ICD generators and threatened to shorten follow-up substantially. If follow-up had been stopped on the date originally planned, but without replacing ICDs, the average follow-up would have fallen from 40 months to about 33 months. Also, in October 1994, the control group mortality rate was found to be somewhat lower than expected. Together, the abbreviated follow-up and lower control group mortality threatened to reduce power substantially. The DSMB reviewed several options for restoring power. Because mortality rates in the first month after CABG surgery were about seven times as high as thereafter and because ICD therapy did not reduce surgical mortality (death during the first 30 days), extending the follow-up benefits power more than does increasing the sample size. However, the limit on extending follow-up was 42 months (the expected battery life of the ICD). Data from the ICD-treated group was not reviewed or considered in making the decision. After reviewing many options for restoring power, the DSMB recommended that the sample size be increased from 800 to 900 patients and that almost all patients be followed for 42 months. This recommendation extended follow-up for 2 years beyond the original termination date planned for the trial and dictated that patients close out after 42 months rather than on a common termination date.

KW - Arrhythmia

KW - Clinical trial

KW - Coronary artery bypass graft surgery

KW - Group sequential monitoring

KW - Implantable cardiac defibrillator

KW - Sample size

KW - Statistical power

KW - Survival analysis

UR - http://www.scopus.com/inward/record.url?scp=0031951524&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0031951524&partnerID=8YFLogxK

U2 - 10.1016/S0197-2456(97)00124-4

DO - 10.1016/S0197-2456(97)00124-4

M3 - Review article

C2 - 9492965

AN - SCOPUS:0031951524

VL - 19

SP - 1

EP - 14

JO - Controlled Clinical Trials

JF - Controlled Clinical Trials

SN - 0197-2456

IS - 1

ER -